Ertugliflozin Linked to Better Renal Function in Type 2 Diabetes

SAN FRANCISCO – L 'ertugliflozine could protect kidney function in patients with type 2 diabetes, according to the results of a study presented at the 79th Scientific Session of the American Diabetes Association, which Is held from June 7 to 11, 2019.

The researchers pooled data from two randomized controlled trials to evaluate the effect of ertugliflozine on renal function measurements. Participants with type 2 diabetes were divided into groups receiving 5 mg of ertugliflozin (n = 652), 15 mg of ertugliflozin (n = 640), or glimepiride or placebo (n = 644). ). Changes in estimated glomerular filtration rate (eGFR) and albumin – creatinine ratio in urine compared to baseline values ​​were badyzed using mixed models including treatment, time, blood pressure, and other changes. glycated hemoglobin, blood pressure and other initial measures as covariates.

Initially, the average GFR was 88.2 mL / min / 1.73 m² and geometric mean UACR was 11.6 mg / g. After 6 weeks, patients receiving 5 or 15 mg of ertugliflozin experienced greater reductions in eGFR compared to patients not receiving ertugliflozin (-2.3 and -2.7 vs. -0, 7 mL / min / 1.73 m², respectively). However, this trend reversed with time for ertugliflozin groups, while reductions in eGFR were observed in the non-ertugliflozin group.

After 2 years, the change in eGFR was 1.81 and 2.10 mL / min / 1.73 m² for the groups receiving ertugliflozine 5 and 15 mg, respectively, compared to patients receiving placebo or glimepiride.

With regard to the average RCAC rate after two years, the groups treated with ertugliflozine at 5 and 15 mg showed respectively a variation of -29.0% and -32.7% compared to the group not receiving ertugliflozine. Patients with albuminuria at baseline (UACR baseline> 30 mg / g, n = 415) experienced greater reductions in UACR response rate after administration of ertugliflozine compared with comparison.

The researchers said the findings suggest a preservation of renal function, given the badociation between the utergliflozine and higher values ​​of eGRF over time.

Follow @EndoAdvisor

Reference

Cherney D, Heerspink HL, Frederich R, et al. Effects of ertugliflozine on renal function for two years. Presented at: American Diabetes Association 79th Scientific Sessions; June 7-11, 2019; San Francisco, CA. Poster 1197-P.